The Davinci Company, LLC

The Davinci Company, LLC, a service-disabled veteran-owned small business based in Greensboro, North Carolina, operates as a 100% prime federal contractor supplying medical and pharmaceutical products, optical instrument components, and defense-related equipment to the Department of Veterans Affairs and the Defense Logistics Agency. The company is a for-profit limited liability partnership certified as SDVOSB and small disadvantaged business, competing predominantly under set-asides across its prime footprint.

The Davinci Company maintains a diversified capability portfolio anchored on two distinct customer segments. For the VA, the vendor supplies diabetic glucose test strips (OneTouch, Contour Next, LifeScan brands), over-the-counter medications, surgical sutures, and pharmaceutical consumables to consolidated mail outpatient pharmacies and Veterans Integrated Service Network facilities nationwide. For the Defense Logistics Agency Land and Maritime division, the company supplies optical instrument components (reticle assemblies, eyepiece assemblies, lens caps, optical instrument cases), mechanical components (access covers, elevation adjusters, filter subassemblies, protective dust caps), and precision equipment items (borescope kits, telescope tool kits, anti-reflection devices). Representative work includes a $694,234 SDVOSB set-aside purchase order from VA VISN 15 (April 2025) for diabetic testing supplies; a $3.699 million full-and-open delivery order from the Office of the Assistant Secretary for Preparedness and Response (September 2026) for sodium chloride saline flush under the Medical Equipment and Supplies Federal Supply Schedule; and a $201,455 SDVOSB set-aside purchase order from DLA Land and Maritime (July 2024) for 3,863 anti-reflection devices.

Customer concentration tracks heavily to two agencies. The Defense Logistics Agency Land and Maritime division dominates by award count at 60 awards (58% of portfolio) carrying $3 million combined potential value, while the Department of Veterans Affairs Veterans Health Administration (across multiple VISNs) accounts for 29 awards (28% of portfolio) carrying $6.1 million combined potential value when aggregated across VA networks. By dollar magnitude, the top five funding entities account for 91% of combined potential value: VA VISN 12 leads at $5.1 million (primarily the $4.9 million Medical Equipment and Supplies Federal Supply Schedule contract awarded February 2025 and the $225,000 Pharmaceuticals FSS contract awarded July 2024), followed by the Office of the Assistant Secretary for Preparedness and Response at $3.7 million, VA VISN 15 at $3.3 million, and DLA Land and Maritime at $3 million. The two customer rankings diverge sharply: DLA issues many small orders (60 awards at $3 million) while VA VISN 12's two awards anchor most of the dollars ($5.1 million).

The Davinci Company holds multiple indefinite delivery vehicles totaling $13.9 million in potential value. The $4.9 million VA FSS contract for medical equipment and supplies (VISN 12, effective February 15, 2025, through February 14, 2030) is the largest single vehicle, covering surgical sutures across over 200 SKUs. The $225,000 VA FSS contract for pharmaceuticals and hematology products (VISN 12, effective July 1, 2024, through June 30, 2029) provides multi-agency ordering authority for glucose test strips and OTC medication replenishment. Five DLA Land and Maritime single-award IDIQs, each with $250,000 ceilings, were awarded between May 2025 and March 2026 for reticle assemblies, eyepiece assemblies, lens caps, small sight mounts, and access covers — vehicles that structure delivery through consolidation and containerization points to CONUS and OCONUS depots. These DLA contracts carry set-aside designations split between Total Small Business and Service-Disabled Veteran-Owned Small Business, while VA FSS vehicles carry no set-aside beyond the vendor's inherent SDVOSB status.

Activity has grown substantially, rising from 7 awards in 2022 to a peak of 35 in 2024, with 27 awards in 2025 and 21 in the first nine months of 2026. The combined obligated value stands at $10.7 million (60% of the $17.9 million combined potential value). Four awards (combined potential value $4 million) face ultimate completion dates within the next twenty-four months, representing moderate recompete exposure in the near term. The vendor's NAICS concentration skews toward Commercial and Service Industry Machinery Manufacturing (39 awards), In-Vitro Diagnostic Substance Manufacturing (28 awards), and Small Arms, Ordnance, and Ordnance Accessories Manufacturing (12 awards), reflecting the dual product mix. The company has no documented subcontractor relationships or subsidiary activity beyond Amerisyn, LLC, a manufacturer subsidiary listed in the corporate structure.